Hematopoietic Stem And Progenitor Cells Improve Survival From Sepsis By Boosting Immunomodulatory Cells

Decorative image of the Sepsis Learning Lounge

Hematopoietic Stem And Progenitor Cells Improve Survival From Sepsis By Boosting Immunomodulatory Cells

SUMMARY

A new preclinical study reports on a novel strategy for treating sepsis using hematopoietic stem and progenitor cells (HSPCs) with the goal of reducing inflammation. HSPC infusions were correlated with higher survival rates in mice infected with Group A Streptococcus induced sepsis.

FEATURED EXPERT

Anthony Flores, MD, PhD, MPH, Associate Professor at UT Houston

GET STARTED

Read the preclinical study at PubMed.

Read time: 30 minutes

Take me there now!

We want to hear from you!

Your feedback helps us continue to provide resources and content specific to your needs.

Take Our Poll

Global Solutions

VIDAS^®B•R•A•H•M•S PCT™

Detects procalcitonin, a biomarker that aids in the risk assessment for progression to severe sepsis and septic shock. PCT also aids in decision making on antibiotic therapy for patients with lower respiratory tract infections (LRTI).

Learn More